"EURbG2": A European prospective study of patients with unilateral retinoblastoma requiring enucleation, either first-line or after neoadjuvant chemotherapy, with analysis of histological risk factors and biomarkers at baseline and during follow-up
Retinoblastoma is a rare cancer of the eye that mostly affects babies and young children. When the cancer is in only one eye and is advanced, doctors often recommend surgery to remove the eye (called enucleation) to completely remove the tumour and protect the child's life. This European study, called EURbG2, follows patients who need this operation. Some children have surgery straight away, while others receive chemotherapy first to shrink the tumour. Researchers will test the removed tumour tissue, blood, and other fluids for 'biomarkers'—tiny biological clues that show how aggressive the tumour is. By matching these clues with how well children recover, doctors hope to learn which patients need extra chemotherapy and which can safely avoid it. The ultimate goal is to provide safer, more tailored care for children with retinoblastoma in the future.
At a glance
What is this study about?
Retinoblastoma is a rare childhood cancer that starts in the retina, the light-sensitive layer at the back of the eye. In most children, it affects only one eye. When a tumour is large or cannot be safely treated with other methods, the most effective and life-saving option is often an operation called enucleation, which gently removes the affected eye.
The EURbG2 study is a Europe-wide research project. It aims to collect and study tumour samples taken during standard surgery, alongside blood and fluid samples. Doctors want to examine the genetic makeup of the tumour and identify 'biomarkers'. These are biological signs that can tell doctors more about how the cancer behaves, whether it might spread, and how likely it is to return.
Depending on the risk level discovered in the tumour, some children may also receive chemotherapy drugs, such as carboplatin, vincristine, or etoposide, to clear any remaining cancer cells. By studying these factors over several years, researchers hope to fine-tune future treatments. This means future patients could receive treatments tailored specifically to their tumour's risk level, helping them get well while avoiding unnecessary medicines and their side effects.
Key takeaways
- The study focuses on unilateral retinoblastoma (cancer in one eye) requiring surgery to remove the eye.
- It aims to find biological clues (biomarkers) to better predict which children need extra chemotherapy.
- Surgery and treatments follow safe, standard medical practices; research samples are taken alongside routine care.
- Patients are followed closely over several years to monitor their recovery and long-term health.
- Taking part is voluntary and helps improve future treatments for children with eye cancer.
Who may be eligible?
This study is designed for patients diagnosed with retinoblastoma affecting only one eye (known as unilateral retinoblastoma). It is open to people of any age, although retinoblastoma almost always affects babies and young children under five years old. Both boys and girls can take part.
To be eligible, the patient's care team must have decided that surgery to remove the affected eye is necessary. This includes children having surgery as their first treatment, as well as those who have already received some chemotherapy to shrink the tumour before surgery.
Children with cancer in both eyes, or those whose eye does not need to be removed, will not be suitable for this specific trial. Your specialist eye doctor or paediatric oncologist can confirm whether this study matches your child's treatment plan.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- The patient has been diagnosed with retinoblastoma in one eye only.
- The medical team has recommended removing the affected eye (enucleation).
- Surgery is either the first treatment or planned after an initial course of chemotherapy.
- The patient is able to attend regular follow-up appointments and scans.
- A parent or guardian is willing to give informed consent for the study.
What does participation involve?
Taking part in this study happens alongside your child's standard medical care. The operation to remove the eye is part of normal treatment, not an experimental procedure. If you agree to join, researchers will collect the tumour tissue after it has been removed, along with routine blood samples and tiny amounts of eye or spinal fluid taken while your child is already asleep under general anaesthetic.
Some children may receive standard chemotherapy drugs (such as vincristine, carboplatin, or etoposide) through a drip, depending on their tumour's risk factors. During treatment and recovery, your child will have routine hospital visits, eye checks, and MRI scans to ensure they stay healthy. Follow-up monitoring will continue for several years to track their long-term health and make sure the cancer has not returned.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is an enucleation?
Enucleation is a common, safe operation to remove the diseased eye. It cures the cancer in the vast majority of cases where the tumour is contained within the eye. Later, a custom-made artificial eye is fitted, which looks very natural and moves alongside the other eye.
Will joining this study delay my child's surgery?
No. Your child's surgery and treatment will go ahead on the normal schedule planned by your medical team. Joining the study simply allows doctors to run detailed laboratory tests on the tumour and routine samples.
Does my child definitely have to have chemotherapy?
Not necessarily. Chemotherapy is only given if the laboratory tests show that the tumour has 'high-risk' features that make the cancer more likely to return or spread. If the risk is low, surgery alone may be all that is needed.
Will taking part hurt my child?
The research team takes great care to keep children comfortable. Extra fluid or blood samples for the study are taken while your child is already asleep for surgery or during tests they would be having anyway, so they will not feel extra needle pricks.
Can I change my mind after agreeing to take part?
Yes, absolutely. You can withdraw from the study at any point without giving a reason. Your child will continue to receive the best possible standard care from their doctors and nurses.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.